Oncology Therapeutics

Turning the Tide on Cancer

Cardiff Oncology is a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer.

focusing on cancer indications with the greatest medical need for new treatments

Featured News & Events

Jan 11, 2022

Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs

Jan 10, 2022

Cardiff Oncology to Host Conference Call and Webcast to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Being Presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Jan 4, 2022

Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference

Targeting a Key Regulatory Enzyme in Tumor Cell Division

We are developing onvansertib, an oral and highly selective inhibitor of polo-like kinase 1 (PLK1), which is over expressed in most cancers.

Our Clinical Programs

KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.

Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Leveraging the synergy of onvansertib to increase duration and response of overall survival.

Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.